Human chorionic gonadotropin (hCG) is considered to be one of the factors which regulate relaxin secretion in humans. Serum immunoreactive relaxin levels are increased and are detectable by radioimmunoassay both in normal and molar pregnancy.
Circulating hCG levels are increased in trophoblastic disease.
In the present study, relaxin and hCG levels were sequentially measured in patients with invasive mole, choriocarcinoma and presistent trophoblastic disease. Serum relaxin levels were detectable by radioimmunoassay in these patients before treatment, though they were significantly lower than in normal pregnancy.
The corpus luteum of pregnancy is the main source of circulating relaxin in normal pregnancy. The existence of a corpus luteum was confirmed in the 2 patients who underwent laparotomy. Consequently, the corpus luteum may also be the main source of circulating relaxin in trophoblastic disease. Parallel changes in hCG and relaxin levels were observed during the courses of trophoblastic disease. The finding suggests that relaxin secretion is dependent on hCG stimulation in trophoblastic disease in the presence of corpus luteum.
Human chorionic gonadotropin (hCG) is considered to be one of the factors which regulate relaxin secretion in humans (Quagliarello et al., 1979; Quagliarello et al., 1980; Weiss et al., 1976) . Serum immunoreactive relaxin levels are increased and detectable by radioimmunoassay (RIA) both in normal (O'Byrne et al., 1978) and molar pregnancy (Seki et al., 1986) . Circulating levels of hCG are increased in patients with invasive mole or choriocarcinoma as in patients with hydatidiform mole. Consequently, the amount of serum relaxin may also be increased in such patients. We now report circulating levels of relaxin and hCG sequentially measured in patients with invasive mole, choriocarcinoma and persistent trophoblastic disease.
Materials and Methods
The subjects of this study were 2 patients with invasive mole, 2 patients with choriocaricnoma and 2 patients with persistent trophoblastic disease. Luteal cysts were detected in none of them. In 5 of the 6 patients, serum relaxin and hCG levels were sequentially measured by RIA before and after the initiation of therapy. In the remaining 1 patients with invasive mole, ralaxin and hCG levels were measured only before therapy. Relaxin was measured by RIA (Sherwood et al., 1975; O'Byrne and Steinetz, 1976) as previous described (Seki et al., 1985) . hCG was measured with RIA kits obtained from Commissariat a l'Energie Atomique, France. The sensitivity of the hCG assay was 2.0 mIU/ml. Statistical analysis was performed using signed rank test. Serum hCG and relaxin concentrations in patients with invasive mole, choriocarcinoma and persistent trophoblastic disease were compared with those in 31 normal women during the first trimester of pregnancy (average 11.2 weeks of pregnancy; range nine to 14) or with those in 7 patients with hydatidiform mole, which had previously been reported elesewhere (Seki et al., 1986) . 
Results
Relaxin and hCG levels before treatment Serum relaxin was detectable before treatment in all 6 patients. The relaxin and hCG concentrations were lower in these patients than in normal women during the first trimester of pregnancy or in patients with hydatidiform mole (Table 1) . There was an overlap in the range of hCG values, but not in that of relaxin values between these patients and those with hydatidiform mole (Table 1) .
Case Reports Invasive mole
In a patient with invasive mole, relaxin levels decreased to an undetectable level 3 days after a total hysterectomy and right salpingo-oophorectomy (Fig. 1) . hCG levels also rapidly decreased, though they were still detectable 3 weeks after operation. A corpus luteum was confirmed by histology in the right ovary.
Choriocarcinoma
A patient with nonmetastatic choriocarcinoma was characterized by a plateau in both hCG and relaxin levels after evacuation (Fig. 2) . A discordant hCG and relaxin profile was noticed.
Although relaxin levels later decreased to an undetectable level, low but detectable levels of hCG persisted.
Then hCG levels showed a rise, followed by a small rise in relaxin levels. After a total hysterectomy and bilateral salpingo-oophorectomy, hCG levels fell rap- Fig. 2 . A 53-year-old woman, gravida 4, para 2, underwent curetage for a hydatidiform mole in June, 1983. After evacuation, hCG and relaxin levels continued to fall through September, and levelled off thereafter until March, 1984 . From April, 1984 Endocrinol. Japon. Octoberidly, but still detectable until 12 days after operation. Relaxin levels became undetectable 3 days after operation.
A corpus luteum was confirmed by histology in the right ovary.
In a patient with metastatic choriocarcinoma, hCG rapidly decreased after initiation of chemotherapy, while relaxin slowly decreased (Fig. 3) .
Persistent trophoblastic disease
In a patient with postmolar persistent trophoblastic disease, the fall in hCG and relaxin levels was retarded after evacuation (Fig. 4) . hCG and relaxin levels did not fall to an undetectable level, and rose later. On initiation of chemotherapy, both relaxin and hCG levels fell. Although relaxin became undetectable within 12 days, hCG did not become undetectable over 2 months. I n a patient with nonmetastatic persistent trophoblastic disease, relaxin levels were low but detectable (0.2 ng/ml) before treatment (Fig. 5) . hCG levels fell steadily during chemotherapy. Relaxin levels were always undetectable after initiation of chemotherapy.
Discussion
Detectable levels of relaxin were found in patients with invasive mole, choriocarcinoma and persistent trophoblastic disease. The corpus luteum of pregnancy is the main Fig. 3 . A 36-year-old woman, gravida 2 , para 1, underwent an emergency craniotomy for a cerebral hemorrhage on January 12, 1983. Pathologic examination revealed tissue consistent with choriocarcinoma. On January 21 , 1983, she was transferred to our department. The serum hCG level was 340,000 mIU/ml. Chest X-ray revealed metastatic lesions in the lungs . She had an hydatidiform mole 4 years before, but had not been regularly followed up. On February 3, 1983, multiple chemotherapy with methotrexate, actinomycin and cyclophosphamide (MAC) was initiated, and the patient received 7 courses. Whole brain irradiation (2,100 rads) was performed with the initial chemotherapy. Serum relaxin was 0.3 ng/ ml, and the hCG level was 400,000 mIU/ml before treatment.
At the time that chemotherapy was discontinued, all evidence of metastasis had disappeared. The patient has been in stable remission since that time. source of circulating immunoreactive relaxin in normal pregnancy (Weiss et al., 1976) . In the 2 patients with trophoblastic disease who underwent a total hysterectomy and extirpation of the ovary containing a corpus luteum, relaxin levels promptly fell and became undetectable within 3 days. On the other hand, the disappearance pattern of relaxin was slower in a patient with metastatic choriocarcinoma treated with chemotherapy. In 1 of the 2 patients with persistent trophoblastic disease, serum relaxin levels were still elevated 5 days after the initiation of chemotherapy. Therefore, the corpus luteum may also be the main source of circulating immunoreactive relaxin in trophoblastic disease, though an extraluteal Fig. 4 . A 34-year-old woman, gravida 4, para 2, underwent evacuation of an hydatidiform mole on April 19, 1983. The titers before evacuation were 650,000 mIU/ml for hCG and 0.8 ng/ml for relaxin. After evacuation, both hCG and relaxin levels fell slowly through September, 1983. However, they plateaued in October, 1983, and increased in November, 1983 level found in our patients with trophoblastic disease compared to normal or molar pregnancy. In a patient with postmolar persistent trophoblastic disease, detectable levels of relaxin were found for 8 months after evacuation of hydatidiform mole. Consequently, the function of the corpus luteum in secreting relaxin may continue as long as stimulation of the corpus luteum by effective hCG persists. While hCG can induce luteal relaxin secretion, constant doses of hCG or luteinizing hormone cannot maintain the nonpregnant corpus luteum for more than 2 addtional weeks (Strott et al., 1969; Hanson et al., 1971; Stock et al., 1971) . Thus, additional factors may be present to account for the continued function of the corpus luteum in secreting relaxin in trophobastic disease. 
